Vistin Pharma - Earnings Release 2018

Vistin Pharma ASA : 20 per cent revenue growth in second quarter 2018

Oslo, Norway, 30 August 2018

Vistin Pharma delivers a revenue growth of 20 percent from NOK 45.3 million in

the second quarter 2017 to NOK 54.6 million in the second quarter 2018. The

underlying demand for metformin is still strong and Vistin sales volume of

metformin as active pharmaceutical ingredients were 22 per cent higher compared

to second quarter 2017. The adjusted EBITDA from the pharmaceutical business

came to NOK 4.3 million for the second quarter, compared to NOK 5.0 million

second quarter last year. The Energy Trading business commenced operations in

the second quarter, and the EBITDA from this business segment came to negative

NOK 0.7 million. EBT from continuing operations for the second quarter came to

negative NOK 16.0 million, which includes an unrealised loss on oil derivatives

of NOK 17.3 million, compared to a profit of NOK 4.9 million in the same quarter

last year.

The Company completed a private placement and subsequent offering of NOK 305

million during the quarter and Vistin Pharma had cash of NOK 333.7 million as of

30 June. The Company holds no interest-bearing debt.

Vistin Pharma will hold a presentation on 4 September at 12:00 CET at Carnegie

AS, Fjordalleen 16, Oslo. CEO Kjell-Erik Nordby, Head of Energy Trading

Torbjørn Kjus and CFO Gunnar Manum will represent the Company. Vistin Pharma

welcomes all interested parties.

Please find the report for the second quarter 2018 enclosed. The report will

also be made available on www.vistin.com.

*****

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

Gunnar Manum

CFO

+47 95 17 91 90

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

AI assistant